{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:02:43Z","timestamp":1792692163691,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumor predisposition syndrome caused by germline fumarate hydratase (<jats:italic toggle=\"yes\">FH<\/jats:italic>) mutations and characterized by uterine and cutaneous leiomyomas and renal cell cancer. Currently, there is no generally approved method to differentiate FH-deficient uterine leiomyomas from other leiomyomas. Here, we analyzed 3 antibodies (S-(2-succino)-cysteine [2SC], aldo-keto reductase family 1, member B10 [AKR1B10], and FH) as potential biomarkers. The study consisted of 2 sample series. The first series included 155 formalin-fixed paraffin-embedded uterine leiomyomas, of which 90 were from HLRCC patients and 65 were sporadic. The second series included 1590 unselected fresh frozen leiomyomas. Twenty-seven tumors were from known HLRCC patients, while the <jats:italic toggle=\"yes\">FH<\/jats:italic> status for the remaining 1563 tumors has been determined by copy number analysis and Sanger sequencing revealing 45 tumors with monoallelic (n=33) or biallelic (n=12) <jats:italic toggle=\"yes\">FH<\/jats:italic> loss. Altogether 197 samples were included in immunohistochemical analyses: all 155 samples from series 1 and 42 available corresponding formalin-fixed paraffin-embedded samples from series 2 (15 tumors with monoallelic and 7 with biallelic <jats:italic toggle=\"yes\">FH<\/jats:italic> loss, 20 with no <jats:italic toggle=\"yes\">FH<\/jats:italic> deletion). Results show that 2SC performed best with 100% sensitivity and specificity. Scoring was straightforward with unambiguously positive or negative results. AKR1B10 identified most tumors accurately with 100% sensitivity and 99% specificity. FH was 100% specific but showed slightly reduced 91% sensitivity. Both FH and AKR1B10 displayed also intermediate staining intensities. We suggest that when patient\u2019s medical history and\/or histopathologic tumor characteristics indicate potential FH-deficiency, the tumor\u2019s FH status is determined by 2SC staining. When aberrant staining is observed, the patient can be directed to genetic counseling and mutation screening.<\/jats:p>","DOI":"10.1097\/pas.0000000000001826","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T01:58:25Z","timestamp":1634954305000},"page":"537-546","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":34,"title":["Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas"],"prefix":"10.1097","volume":"46","author":[{"given":"Terhi","family":"Ahvenainen","sequence":"first","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Medical and Clinical Genetics, University of Helsinki"},{"name":"iCAN Digital Precision Cancer Medicine Flagship"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaana","family":"Kaukomaa","sequence":"additional","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Medical and Clinical Genetics, University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"K\u00e4mpj\u00e4rvi","sequence":"additional","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Medical and Clinical Genetics, University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Uimari","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Oulu University Hospital"},{"name":"PEDEGO Research Unit, University of Oulu and Oulu University Hospital"},{"name":"Medical Research Center Oulu, Oulu University Hospital, University of Oulu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ahtikoski","sequence":"additional","affiliation":[{"name":"Medical Research Center Oulu, Oulu University Hospital, University of Oulu"},{"name":"Department of Pathology, Oulu University Hospital"},{"name":"Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netta","family":"M\u00e4kinen","sequence":"additional","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Medical and Clinical Genetics, University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskari","family":"Heikinheimo","sequence":"additional","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Obstetrics and Gynecology, Helsinki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri A.","family":"Aaltonen","sequence":"additional","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Medical and Clinical Genetics, University of Helsinki"},{"name":"iCAN Digital Precision Cancer Medicine Flagship"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auli","family":"Karhu","sequence":"additional","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Medical and Clinical Genetics, University of Helsinki"},{"name":"iCAN Digital Precision Cancer Medicine Flagship"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Pathology, Laboratory of Helsinki University Hospital (HUSLAB), Helsinki University Hospital and University of Helsinki, Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Vahteristo","sequence":"additional","affiliation":[{"name":"Applied Tumor Genomics Research Program"},{"name":"Department of Medical and Clinical Genetics, University of Helsinki"},{"name":"iCAN Digital Precision Cancer Medicine Flagship"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"16043","DOI":"10.1038\/nrdp.2016.43","article-title":"Uterine fibroids","volume":"2","author":"Stewart","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"211.e1","DOI":"10.1016\/j.ajog.2011.12.002","article-title":"The estimated annual cost of uterine leiomyomata in the United States","volume":"206","author":"Cardozo","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.1518752113","article-title":"Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers","volume":"113","author":"Mehine","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"R5-20250612","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41586-021-03747-1","article-title":"Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma","volume":"596","author":"Berta","year":"2021","journal-title":"Nature"},{"key":"R6-20250612","article-title":"Frequency of MED12 mutation in relation to tumor and patient\u2019s clinical characteristics: a meta-analysis","author":"He","year":"2021","journal-title":"Reprod Sci"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.fertnstert.2014.06.050","article-title":"Genomics of uterine leiomyomas: insights from high-throughput sequencing","volume":"102","author":"Mehine","year":"2014","journal-title":"Fertil Steril"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1073\/pnas.051633798","article-title":"Inherited susceptibility to uterine leiomyomas and renal cell cancer","volume":"98","author":"Launonen","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1086\/320124","article-title":"Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43","volume":"68","author":"Alam","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-020-01653-9","article-title":"Hereditary leiomyomatosis and renal cell carcinoma: a case series and literature review","volume":"16","author":"Chayed","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R12-20250612","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1001\/archdermatol.2008.517","article-title":"Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer","volume":"144","author":"Stewart","year":"2008","journal-title":"Arch Dermatol"},{"key":"R13-20250612","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/376435","article-title":"Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America","volume":"73","author":"Toro","year":"2003","journal-title":"Am J Hum Genet"},{"key":"R14-20250612","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/humrep\/des105","article-title":"Strong family history of uterine leiomyomatosis warrants fumarate hydratase mutation screening","volume":"27","author":"Tolvanen","year":"2012","journal-title":"Hum Reprod"},{"key":"R15-20250612","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/modpathol.2013.215","article-title":"Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry","volume":"27","author":"Reyes","year":"2014","journal-title":"Mod Pathol"},{"key":"R16-20250612","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000703","article-title":"Fumarase-deficient uterine leiomyomas: an immunohistochemical, molecular genetic, and clinicopathologic study of 86 cases","volume":"40","author":"Miettinen","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R17-20250612","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0000000000000573","article-title":"Fumarate hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings","volume":"40","author":"Harrison","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R18-20250612","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/PAS.0000000000000840","article-title":"Immunohistochemical characterization of fumarate hydratase (FH) and succinate dehydrogenase (SDH) in cutaneous leiomyomas for detection of familial cancer syndromes","volume":"41","author":"Carter","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R19-20250612","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/PAS.0000000000000520","article-title":"Morphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patients","volume":"39","author":"Joseph","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R20-20250612","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/DAD.0000000000000580","article-title":"Loss of fumarate hydratase and aberrant protein succination detected with S-(2-succino)-cysteine staining to identify patients with multiple cutaneous and uterine leiomyomatosis and hereditary leiomyomatosis and renal cell cancer syndrome","volume":"38","author":"Llamas-Velasco","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"R21-20250612","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J Pathol"},{"key":"R22-20250612","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/bjc.2016.130","article-title":"MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas","volume":"114","author":"K\u00e4mpj\u00e4rvi","year":"2016","journal-title":"Br J Cancer"},{"key":"R23-20250612","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1126\/science.1208930","article-title":"MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas","volume":"334","author":"M\u00e4kinen","year":"2011","journal-title":"Science"},{"key":"R24-20250612","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.fertnstert.2014.06.040","article-title":"MED12 mutation frequency in unselected sporadic uterine leiomyomas","volume":"102","author":"Heinonen","year":"2014","journal-title":"Fertil Steril"},{"key":"R25-20250612","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41598-017-01199-0","article-title":"Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas","volume":"7","author":"Heinonen","year":"2017","journal-title":"Sci Rep"},{"key":"R26-20250612","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/bjc.2017.361","article-title":"Global metabolomic profiling of uterine leiomyomas","volume":"117","author":"Heinonen","year":"2017","journal-title":"Br J Cancer"},{"key":"R27-20250612","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9440(10)63091-X","article-title":"Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors","volume":"164","author":"Lehtonen","year":"2004","journal-title":"Am J Pathol"},{"key":"R28-20250612","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","article-title":"VarSome: the human genomic variant search engine","volume":"35","author":"Kopanos","year":"2019","journal-title":"Bioinformatics"},{"key":"R29-20250612","doi-asserted-by":"crossref","first-page":"D886","DOI":"10.1093\/nar\/gky1016","article-title":"CADD: predicting the deleteriousness of variants throughout the human genome","volume":"47","author":"Rentzsch","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R30-20250612","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc1013","article-title":"A role for mitochondrial enzymes in inherited neoplasia and beyond","volume":"3","author":"Eng","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"R31-20250612","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","article-title":"Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations","volume":"14","author":"Pollard","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R32-20250612","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2006.03.005","article-title":"S-(2-succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate","volume":"450","author":"Alderson","year":"2006","journal-title":"Arch Biochem Biophys"},{"key":"R33-20250612","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R34-20250612","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03602530802431439","article-title":"The aldo-keto reductase superfamily and its role in drug metabolism and detoxification","volume":"40","author":"Barski","year":"2008","journal-title":"Drug Metab Rev"},{"key":"R36-20250612","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/PAS.0000000000001293","article-title":"Detailed morphologic and immunohistochemical characterization of myomectomy and hysterectomy specimens from women with hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC)","volume":"43","author":"Chan","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R37-20250612","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/hmg\/ddg148","article-title":"Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency","volume":"12","author":"Alam","year":"2003","journal-title":"Hum Mol Genet"},{"key":"R38-20250612","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2350-9-20","article-title":"The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency","volume":"9","author":"Bayley","year":"2008","journal-title":"BMC Med Genet"},{"key":"R39-20250612","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/cup.12396","article-title":"Fumarate hydratase immunohistochemical staining may help to identify patients with multiple cutaneous and uterine leiomyomatosis (MCUL) and hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome","volume":"41","author":"Llamas-Velasco","year":"2014","journal-title":"J Cutan Pathol"},{"key":"R40-20250612","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/PAS.0000000000001222","article-title":"Prospective detection of germline mutation of fumarate hydratase in women with uterine smooth muscle tumors using pathology-based screening to trigger genetic counseling for hereditary leiomyomatosis renal cell carcinoma syndrome: a 5-year single institutional experience","volume":"43","author":"Rabban","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R42-20250612","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1093\/hmg\/ddv177","article-title":"Clonally related uterine leiomyomas are common and display branched tumor evolution","volume":"24","author":"Mehine","year":"2015","journal-title":"Hum Mol Genet"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T17:00:44Z","timestamp":1749747644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001826","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}